Meloxicam as an adjuvant to peginterferon-α-2a and ribavirin treatment for genotype 1 chronic hepatitis C: A randomized trial

被引：0

作者：

Kagawa, Tatehiro ^{[1
]}

Kojima, Sei-ichiro ^{[2
]}

Shiraishi, Koichi ^{[1
]}

Hirose, Shunji ^{[1
]}

Arase, Yoshitaka ^{[1
]}

Takashimizu, Shinji ^{[2
]}

Watanabe, Norihito ^{[2
]}

Nagata, Naruhiko ^{[3
]}

Numata, Makoto ^{[3
]}

Shiozawa, Hirokazu ^{[4
]}

Nishizaki, Yasuhiro ^{[4
]}

Toki, Mayu ^{[5
]}

Sugita, Teruji ^{[5
]}

Nomura, Kijuro ^{[6
]}

Sakaguchi, Takashi ^{[7
]}

Atsukawa, Kazuhiro ^{[7
]}

Tajima, Hiroto ^{[8
]}

Tei, Yoshihiro ^{[8
]}

Inomoto, Tsutomu ^{[9
]}

Mine, Tetsuya ^{[1
]}

机构：

[1] Tokai Univ, Sch Med, Dept Internal Med, Div Gastroenterol, Isehara, Kanagawa 2591193, Japan

[2] Tokai Univ, Hachioji Hosp, Dept Internal Med, Div Gastroenterol, Hachioji, Tokyo, Japan

[3] Tokai Univ, Oiso Hosp, Dept Internal Med, Div Gastroenterol, Nakagun, Japan

[4] Tokai Univ, Tokyo Hosp, Dept Internal Med, Div Gastroenterol, Tokyo 151, Japan

[5] Yamachika Mem Hosp, Odawara, Japan

[6] Nomura Shokakinaika, Chigasaki, Kanagawa, Japan

[7] Hiratsuka City Hosp, Hiratsuka, Kanagawa, Japan

[8] Japan Med Alliance Ebina Gen Hosp, Ebina, Kanagawa, Japan

[9] Yugawara Kosei Nenkin Hosp, Ashigarashimogun, Japan

来源：

HEPATOLOGY RESEARCH | 2013年 / 43卷 / 09期

关键词：

adjuvant; chronic hepatitis C; cyclooxygenase-2; inhibitor; interferon; meloxicam; neutropenia; NONSTEROIDAL ANTIINFLAMMATORY DRUG; PEGYLATED-INTERFERON-ALPHA; VIROLOGICAL RESPONSE; VIRUS-INFECTION; PLUS RIBAVIRIN; THERAPY; COMBINATION; KETOPROFEN; CYCLOOXYGENASE-2; TELAPREVIR;

D O I：

10.1111/hepr.12046

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Aim: In this multicenter, randomized trial, we evaluated the effectiveness of meloxicam - a non-steroidal anti-inflammatory drug - as an adjuvant for enhancing antiviral efficacy and preventing neutropenia during the treatment of patients with genotype 1 chronic hepatitis C using peginterferon and ribavirin. Methods: A total of 60 patients were randomly assigned, in a 1:1 ratio, to either the meloxicam or the control group after stratification by neutrophil count. Both groups received weekly peginterferon-alpha-2a (180g) and a weight-based dose of ribavirin for 48 weeks. The meloxicam group received meloxicam (10mg/day) for the first 8 weeks after initiation of treatment. Results: Through intent-to-treat analysis, we found that the sustained virological response rate in the meloxicam group (19/30, 63.3%) was significantly higher than in the control group (11/30, 36.7%, P<0.05). The relapse rate was more than twice as high (45%) in the control group than in the meloxicam group (19.0%); however, this difference was not statistically significant. The rate of neutrophil decrease, calculated by dividing the lowest value observed during the first 8 weeks by pretreatment count, was significantly smaller in the meloxicam group (55.1 +/- 14.3%) than in the control group (62.3 +/- 9.6%, P<0.05). Conclusion: Meloxicam enhanced antiviral efficacy and reduced the decline in neutrophil counts for the peginterferon and ribavirin treatment of genotype 1 chronic hepatitis C. This drug could be a reasonable adjuvant for the treatment of patients with chronic hepatitis C. The present study including a small number of patients warrants larger clinical trials.

引用

页码：925 / 932

页数：8

共 26 条

[11] Prevalence of hepatitis C virus genotype 1a in Japan and correlation of mutations in the NS5A region and single-nucleotide polymorphism of interleukin-28B with the response to combination therapy with pegylated-interferon-alpha 2b and ribavirin [J].

Hayashi, Kazuhiko ;

Katano, Yoshiaki ;

Kuzuya, Teiji ;

Tachi, Yoshihiko ;

Honda, Takashi ;

Ishigami, Masatoshi ;

Itoh, Akihiro ;

Hirooka, Yoshiki ;

Ishikawa, Tetsuya ;

Nakano, Isao ;

Urano, Fumihiro ;

Yoshioka, Kentaro ;

Toyoda, Hidenori ;

Kumada, Takashi ;

Goto, Hidemi .

JOURNAL OF MEDICAL VIROLOGY, 2012, 84 (03) :438-444

[12] Meloxicam, an inhibitor of cyclooxygenase-2, increases the level of serum G-CSF and might be usable as an auxiliary means in G-CSF therapy [J].

Hofer, M. ;

Pospisil, M. ;

Znojil, V. ;

Hola, J. ;

Vacek, A. ;

Streitova, D. .

PHYSIOLOGICAL RESEARCH, 2008, 57 (02) :307-310

[13] Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection [J].

Jacobson, Ira M. ;

McHutchison, John G. ;

Dusheiko, Geoffrey ;

Di Bisceglie, Adrian M. ;

Reddy, K. Rajender ;

Bzowej, Natalie H. ;

Marcellin, Patrick ;

Muir, Andrew J. ;

Ferenci, Peter ;

Flisiak, Robert ;

George, Jacob ;

Rizzetto, Mario ;

Shouval, Daniel ;

Sola, Ricard ;

Terg, Ruben A. ;

Yoshida, Eric M. ;

Adda, Nathalie ;

Bengtsson, Leif ;

Sankoh, Abdul J. ;

Kieffer, Tara L. ;

George, Shelley ;

Kauffman, Robert S. ;

Zeuzem, Stefan .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (25) :2405-2416

[14] Eight-week oral administration of meloxicam, a non-steroidal anti-inflammatory drug, prevents dose reduction of pegylated interferon α-2a in the treatment of chronic hepatitis C [J].

Kagawa, Tatehiro ;

Shiozawa, Hirokazu ;

Kojima, Sei-Ichiro ;

Takashimizu, Shinji ;

Nagata, Naruhiko ;

Numata, Makoto ;

Morino, Fumitoshi ;

Nishizaki, Yasuhiro ;

Mochizuki, Kaori ;

Watanabe, Norihito ;

Watanabe, Tetsu ;

Matsuzaki, Shohei ;

Mine, Tetsuya .

HEPATOLOGY RESEARCH, 2008, 38 (03) :259-266

[15] Quantification of hepatitis C virus in patients treated with peginterferon-alfa 2a plus ribavirin treatment by COBAS TaqMan HCV test [J].

Kanda, T. ;

Imazeki, F. ;

Yonemitsu, Y. ;

Mikami, S. ;

Takada, N. ;

Nishino, T. ;

Takashi, M. ;

Tsubota, A. ;

Kato, K. ;

Sugiura, N. ;

Tawada, A. ;

Wu, S. ;

Tanaka, T. ;

Nakamoto, S. ;

Mikata, R. ;

Tada, M. ;

Chiba, T. ;

Kurihara, T. ;

Arai, M. ;

Fujiwara, K. ;

Kanai, F. ;

Yokosuka, O. .

JOURNAL OF VIRAL HEPATITIS, 2011, 18 (07) :E292-E297

[16] Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1 [J].

Lok, Anna S. ;

Gardiner, David F. ;

Lawitz, Eric ;

Martorell, Claudia ;

Everson, Gregory T. ;

Ghalib, Reem ;

Reindollar, Robert ;

Rustgi, Vinod ;

McPhee, Fiona ;

Wind-Rotolo, Megan ;

Persson, Anna ;

Zhu, Kurt ;

Dimitrova, Dessislava I. ;

Eley, Timothy ;

Guo, Tong ;

Grasela, Dennis M. ;

Pasquinelli, Claudio .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (03) :216-224

[17] Interferon-α 2b combined with daily ketoprofen administration improves virological response in chronic hepatitis C:: a prospective and randomised trial [J].

Muñoz, AE ;

Levi, D ;

Podestá, A ;

Gorín, JM ;

González, J ;

Bartellini, MA ;

Munne, MS ;

Cabanne, A ;

Flichman, D ;

Terg, R .

GUT, 2000, 46 (03) :427-431

[18] Boceprevir for Untreated Chronic HCV Genotype 1 Infection [J].

Poordad, Fred ;

McCone, Jonathan, Jr. ;

Bacon, Bruce R. ;

Bruno, Savino ;

Manns, Michael P. ;

Sulkowski, Mark S. ;

Jacobson, Ira M. ;

Reddy, K. Rajender ;

Goodman, Zachary D. ;

Boparai, Navdeep ;

DiNubile, Mark J. ;

Sniukiene, Vilma ;

Brass, Clifford A. ;

Albrecht, Janice K. ;

Bronowicki, Jean-Pierre ;

Colombato, L. ;

Curciarello, J. ;

Silva, M. ;

Tanno, H. ;

Terg, R. ;

Adler, M. ;

Langlet, P. ;

Lasser, L. ;

Nevens, F. ;

Anderson, F. ;

Bailey, R. ;

Bilodeau, M. ;

Cooper, C. ;

Feinman, S. V. ;

Heathcote, J. ;

Levstik, M. ;

Ramji, A. ;

Sherman, M. ;

Shafran, S. ;

Yoshida, E. ;

Achim, A. ;

Ben Ali, S. ;

Bigard, M-A. ;

Bonny, C. ;

Bourliere, M. ;

Boyer-Darrigrand, N. ;

Bronowicki, J-P. ;

Canva, V. ;

Couzigou, P. ;

De Ledinghen, V. ;

Guyader, D. ;

Hezode, C. ;

Larrey, D. ;

Latournerie, M. ;

Marcellin, P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (13) :1195-1206

[19] Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection [J].

Sherman, Kenneth E. ;

Flamm, Steven L. ;

Afdhal, Nezam H. ;

Nelson, David R. ;

Sulkowski, Mark S. ;

Everson, Gregory T. ;

Fried, Michael W. ;

Adler, Michael ;

Reesink, Hendrik W. ;

Martin, Marie ;

Sankoh, Abdul J. ;

Adda, Nathalie ;

Kauffman, Robert S. ;

George, Shelley ;

Wright, Christopher I. ;

Poordad, Fred .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (11) :1014-1024

[20] Pitavastatin enhances antiviral efficacy of standard pegylated interferon plus ribavirin in patients with chronic hepatitis C: A prospective randomized pilot study [J].

Shimada, Masahiko ;

Yoshida, Shuhei ;

Masuzaki, Ryota ;

Schuppan, Detlef .

JOURNAL OF HEPATOLOGY, 2012, 56 (01) :299-300

← 1 2 3 →